Merck KGaA
https://www.merckgroup.com/en
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Merck KGaA
Five Multiple Sclerosis R&D Updates From ECTRIMS
With the virtual doors about to close on the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting, Scrip takes a look at some of the highlights, including data for Merck KGaA and Sanofi’s new BTK inhibitors and research showing the impact of MS therapies on COVID-19 vaccine response.
Apnimed Moves Closer To Phase III With Sleep Apnea Drug
Apnimed is going to conduct one more Phase II study in sleep apnea, mainly to assess subjective endpoint questionnaires, and then hopes to launch a Phase III program by autumn of 2022.
MoonLake Takes SPAC Route To Challenge Novartis's Cosentyx
MoonLake of Switzerland is heading to the NASDAQ armed with $230m to take its tri-specific IL17A/IL-17F nanobody sonelokimab, acquired from Merck KGaA, into the highly competitive spaces of psoriatic arthritis, ankylosing spondylitis and hidradenitis suppurativa.
GSK Exits $4.2bn Cancer Drug Deal With Merck KGaA After Multiple Failures
Bintrafusp alfa was once seen as a blockbuster contender by the partners but GSK’s withdrawal narrows further its chances of success.
Company Information
- Industry
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Pharmaceuticals
- Drug Delivery
- Nutraceuticals
-
Biotechnology
- Synthesis Technologies, Production Processes
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
- Other Names / Subsidiaries
-
- Acadiana Ventures Inc.
- Allergopharma Joachim Ganzer KG
- AmpTec GmbH
- Asceneuron
- EMD Pharmaceuticals
- Grzybowski Scientific Inventions (GSI)
- Intermolecular Inc
- JRH Biosciences
- Merck Hoei Ltd.
- Millipore
- MilliporeSigma
- Ormet Circuts Inc.
- Serono
- EMD Serono, Inc.
- Sigma-Aldrich
- Versum Materials, Inc.